Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MELK | Q14680 | 6/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.42 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.42 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17976248 | 0.90 | DRD4 (0.47) | DRD4NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL17976220 | 0.89 | OPRK1 (0.49) | DRD4AURKAOPRK1SIGMAR1 | |
| SCHEMBL17976036 | 0.88 | OPRK1 (0.48) | DRD4ALDH1A1OPRK1SIGMAR1 | |
| SCHEMBL436539 | 0.83 | DRD4 (0.50) | DRD4NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL12359040 | 0.83 | DRD4 (0.67) | DRD4NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL22820275 | 0.81 | NPC1 (0.43) | DRD4NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL4490990 | 0.79 | DRD4 (0.46) | DRD4NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL7340748 | 0.79 | HDAC1 (0.51) | DRD4NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL520985 | 0.78 | AURKA (0.45) | DRD4NPC1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL7347126 | 0.77 | HDAC1 (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3056202-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-17 | — | — | EP | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | DRD4 1051/4885NPC1 3787/4885LMNA 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.